Journal Home
Search for

Volume 91, Issue 5, Pages 1842-1847 (May 2009)


View previous. 40 of 112 View next.

Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40

Marco Sbracia, M.D.aCorresponding Author Informationemail address, Julio Colabianchi, M.D.b, Annalise Giallonardo, M.D.b, Pierluigi Giannini, M.D.b, Claudio Piscitelli, M.D.b, Francesco Morgia, M.S.b, Monica Montigiani, M.S.b, Mauro Schimberni, M.D.b

Received 12 December 2007; received in revised form 26 February 2008; accepted 26 February 2008. published online 23 May 2008.

Objective

To determine which protocols work better between cetrorelix and long protocols in older patients in a randomized controlled study.

Design

A controlled randomized study in a single private IVF center.

Setting

Infertile women referred to a private IVF center.

Patient(s)

Five hundred sixty-four women 40 years or older undergoing IVF.

Intervention(s)

At their first IVF cycle, the women were randomized into two study groups using a computer-generated number sequence: 281 cases were treated with the cetrorelix protocol, and 283 patients were treated with a long protocol for controlled ovarian hyperstimulation.

Main Outcome Measure(s)

Days of stimulation, E2 on the day of hCG administration, amount of FSH administered, number of oocytes yielded, number of embryos obtained, pregnancy rate, and implantation rate.

Result(s)

Patients treated with the long protocol showed a significantly higher number of oocytes retrieved and a higher pregnancy rate for both the cycle and transfer with respect to the cetrorelix protocol patients. The other parameter evaluated did not show any statistically significant differences.

Conclusion(s)

Our study showed that the long protocol performed better in older women than the cetrorelix protocol and that the GnRH antagonist may be detrimental in older women.

a Center of Endocrinology and Reproductive Medicine, Rome, Italy

b Bioroma, Rome, Italy

Corresponding Author InformationReprint requests: Marco Sbracia, M.D., Center for Endocrinology and Reproductive Medicine, Via Carlo Porta 10, 00153, Rome, Italy (FAX: 39-06-5880096).

 M.S. has nothing to disclose. J.C. has nothing to disclose. A.G. has nothing to disclose. P.G. has nothing to disclose. C.P. has nothing to disclose. F.M. has nothing to disclose. M.M. has nothing to disclose. M.S. has nothing to disclose.

PII: S0015-0282(08)00525-6

doi:10.1016/j.fertnstert.2008.02.165


View previous. 40 of 112 View next.